Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

55.61 -0.43 (-0.77%)
Official Closing Price Updated: 7:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs
To gain an edge, this is what you need to know today. 
Via Benzinga
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Via Stocktwits
Topics Intellectual Property
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.
Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story. 
Via The Motley Fool
3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now
These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples. 
Via The Motley Fool
Topics World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
The latest data from the company's oral weight loss drug is bullish for the stock. 
Via The Motley Fool
Topics Economy
3 Reasons to Buy Novo Nordisk Stock Right Now
The pharmaceutical leader is gradually laying the groundwork for a strong rebound. 
Via The Motley Fool
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
 
Via Benzinga
Topics ETFs
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug. 
Via Investor's Business Daily
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
Roche Targets Top Spot In Weight Loss Drug Market
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
3 Dirt-Cheap Stocks to Buy Right Now
These stocks share several common denominators, including attractive valuations. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market
Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock
Novo Nordisk (NVO) is a top GARP stock with strong growth, exceptional profitability, and a reasonable valuation, making it a compelling investment opportunity. 
Via Chartmill
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Is Novo Nordisk Stock a Buy Now?
A lot has gone wrong for the drugmaker recently. 
Via The Motley Fool
Topics Economy
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies. 
Via Benzinga
Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market
Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its... 
Via MarketMinute
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like... 
Via MarketMinute
Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds
Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown. 
Via Benzinga
The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors.
Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.